Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 07, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital transactions.
- Shares Repurchased: 2,950,000 ordinary shares.
- Repurchase Price: 1,323.8499 pence per share.
- Treasury Shares Held: 385,377,158 shares (representing 6.83% of total voting rights).
- Shares in Issue: 5,637,264,669 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the increase in the company's Treasury share holdings following the September 07, 2007 transaction. The filing does not provide comparative data against prior periods for financial performance or other operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating that the announcement does not constitute an offer or solicitation to purchase securities and confirms conformity with the Transparency Directive's transitional provision 6. No specific risks or contingencies are detailed in this report.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (385,377,158) and the corresponding percentage of voting rights (6.83%).
- Confirm the total number of shares in issue excluding Treasury shares (5,637,264,669) for disclosure threshold calculations.
- Review the specific price paid per share (1,323.8499 pence) to assess the cost of the capital return program.
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly reports for revenue and earnings data.